Us Renal Care Cheektowaga Dialysis is a medicare approved dialysis facility center in Cheektowaga, New York and it has 13 dialysis stations. It is located in Erie county at 2875 Union Road, Suite 13 C/d, Cheektowaga, NY, 14227. You can reach out to the office of Us Renal Care Cheektowaga Dialysis at (716) 684-0276. This dialysis clinic is run as an Independent entity i.e it is not owned by any chain organization. Us Renal Care Cheektowaga Dialysis has the following ownership type - Profit. It was first certified by medicare in December, 2011. The medicare id for this facility is 332686 and it accepts patients under medicare ESRD program.
| Name | Us Renal Care Cheektowaga Dialysis |
|---|---|
| Location | 2875 Union Road, Suite 13 C/d, Cheektowaga, New York |
| No. of Dialysis Stations | 13 |
| Medicare ID | 332686 |
| Managed By | Independent |
| Ownership Type | Profit |
| Late Shifts | No |
| 2875 Union Road, Suite 13 C/d, Cheektowaga, New York, 14227 | |
| (716) 684-0276 | |
News Archive
EraGen Biosciences Inc., Madison, Wis., was congratulated today by SeqWright, Inc., Houston, on EraGen's successful FDA 510(k) market clearance of its MultiCode-RTx HSV 1 & 2 Kit. This new kit is the first FDA-cleared PCR-based qualitative in vitro diagnostic test for the detection and typing of HSV-1 and HSV-2 from vaginal lesion swab specimens in symptomatic female patients.
A novel drug may help increase the effectiveness of radiation therapy for the most deadly form of brain cancer, report scientists at Virginia Commonwealth University Massey Cancer Center. In mouse models of human glioblastoma multiforme (GBM), the new drug helped significantly extend survival when used in combination with radiation therapy.
SironRX Therapeutics Inc., a privately-held, clinical-stage biotechnology company developing novel regenerative therapies to prevent scarring and promote dermal wound repair, is pleased to report that it has completed enrollment of patients in Cohort 1 of its placebo-controlled, randomized, dose escalation double-blind clinical study evaluating the safety and efficacy of JVS-100 to reduce scar formation and improve wound healing in patients receiving surgical sternotomy incisions.
While adverse reactions from smallpox vaccinations given to military personnel in the wake of renewed threats of bioterrorism remain minimal, the rate of cardiac complications has been higher than expected, according to a clinical review presented at an American Medical Society media briefing on cardiology today.
› Verified 5 days ago
| NPI Number | 1629370267 |
| Organization Name | Us Renal Care Cheektowaga Dialysis |
| Doing Business As | Usrc Cheektowaga Inc |
| Address | 2875 Union Rd Cheektowaga, New York, 14227 |
| Phone Number | (716) 684-0276 |
News Archive
EraGen Biosciences Inc., Madison, Wis., was congratulated today by SeqWright, Inc., Houston, on EraGen's successful FDA 510(k) market clearance of its MultiCode-RTx HSV 1 & 2 Kit. This new kit is the first FDA-cleared PCR-based qualitative in vitro diagnostic test for the detection and typing of HSV-1 and HSV-2 from vaginal lesion swab specimens in symptomatic female patients.
A novel drug may help increase the effectiveness of radiation therapy for the most deadly form of brain cancer, report scientists at Virginia Commonwealth University Massey Cancer Center. In mouse models of human glioblastoma multiforme (GBM), the new drug helped significantly extend survival when used in combination with radiation therapy.
SironRX Therapeutics Inc., a privately-held, clinical-stage biotechnology company developing novel regenerative therapies to prevent scarring and promote dermal wound repair, is pleased to report that it has completed enrollment of patients in Cohort 1 of its placebo-controlled, randomized, dose escalation double-blind clinical study evaluating the safety and efficacy of JVS-100 to reduce scar formation and improve wound healing in patients receiving surgical sternotomy incisions.
While adverse reactions from smallpox vaccinations given to military personnel in the wake of renewed threats of bioterrorism remain minimal, the rate of cardiac complications has been higher than expected, according to a clinical review presented at an American Medical Society media briefing on cardiology today.
› Verified 5 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that nephrologists always communicated and cared for them. | 74% | 67% |
| Patients who reported that nephrologists usually communicated and cared for them. | 11% | 15% |
| Patients who reported that nephrologists sometimes or never communicated and cared for them. | 15% | 18% |
| Patients who gave their nephrologists a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 65% | 60% |
| Patients who gave their nephrologists a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 23% | 26% |
| Patients who gave their nephrologists a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 12% | 14% |
News Archive
EraGen Biosciences Inc., Madison, Wis., was congratulated today by SeqWright, Inc., Houston, on EraGen's successful FDA 510(k) market clearance of its MultiCode-RTx HSV 1 & 2 Kit. This new kit is the first FDA-cleared PCR-based qualitative in vitro diagnostic test for the detection and typing of HSV-1 and HSV-2 from vaginal lesion swab specimens in symptomatic female patients.
A novel drug may help increase the effectiveness of radiation therapy for the most deadly form of brain cancer, report scientists at Virginia Commonwealth University Massey Cancer Center. In mouse models of human glioblastoma multiforme (GBM), the new drug helped significantly extend survival when used in combination with radiation therapy.
SironRX Therapeutics Inc., a privately-held, clinical-stage biotechnology company developing novel regenerative therapies to prevent scarring and promote dermal wound repair, is pleased to report that it has completed enrollment of patients in Cohort 1 of its placebo-controlled, randomized, dose escalation double-blind clinical study evaluating the safety and efficacy of JVS-100 to reduce scar formation and improve wound healing in patients receiving surgical sternotomy incisions.
While adverse reactions from smallpox vaccinations given to military personnel in the wake of renewed threats of bioterrorism remain minimal, the rate of cardiac complications has been higher than expected, according to a clinical review presented at an American Medical Society media briefing on cardiology today.
› Verified 5 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that dialysis center staff always communicated well, kept patients comfortable and pain-free as possible. | 60% | 62% |
| Patients who reported that dialysis center staff usually communicated, kept patients comfortable and pain-free as possible. | 20% | 20% |
| Patients who reported that dialysis center staff sometimes or never communicated, kept patients comfortable and pain-free. | 20% | 18% |
| Patients who gave their dialysis facility staff a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 65% | 62% |
| Patients who gave their dialysis facility staff a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 23% | 26% |
| Patients who gave their dialysis facility staff a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 12% | 12% |
News Archive
EraGen Biosciences Inc., Madison, Wis., was congratulated today by SeqWright, Inc., Houston, on EraGen's successful FDA 510(k) market clearance of its MultiCode-RTx HSV 1 & 2 Kit. This new kit is the first FDA-cleared PCR-based qualitative in vitro diagnostic test for the detection and typing of HSV-1 and HSV-2 from vaginal lesion swab specimens in symptomatic female patients.
A novel drug may help increase the effectiveness of radiation therapy for the most deadly form of brain cancer, report scientists at Virginia Commonwealth University Massey Cancer Center. In mouse models of human glioblastoma multiforme (GBM), the new drug helped significantly extend survival when used in combination with radiation therapy.
SironRX Therapeutics Inc., a privately-held, clinical-stage biotechnology company developing novel regenerative therapies to prevent scarring and promote dermal wound repair, is pleased to report that it has completed enrollment of patients in Cohort 1 of its placebo-controlled, randomized, dose escalation double-blind clinical study evaluating the safety and efficacy of JVS-100 to reduce scar formation and improve wound healing in patients receiving surgical sternotomy incisions.
While adverse reactions from smallpox vaccinations given to military personnel in the wake of renewed threats of bioterrorism remain minimal, the rate of cardiac complications has been higher than expected, according to a clinical review presented at an American Medical Society media briefing on cardiology today.
› Verified 5 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that 'YES', their nephrologists and dialysis center staff provided them the information they needed to take care of them. | 74% | 80% |
| Patients who reported that 'NO', their nephrologists and dialysis center staff does not provided them the information they needed to take care of them. | 26% | 20% |
| Patients who gave their dialysis center a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 71% | 68% |
| Patients who gave their dialysis center a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 16% | 20% |
| Patients who gave their dialysis center a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 13% | 12% |
News Archive
EraGen Biosciences Inc., Madison, Wis., was congratulated today by SeqWright, Inc., Houston, on EraGen's successful FDA 510(k) market clearance of its MultiCode-RTx HSV 1 & 2 Kit. This new kit is the first FDA-cleared PCR-based qualitative in vitro diagnostic test for the detection and typing of HSV-1 and HSV-2 from vaginal lesion swab specimens in symptomatic female patients.
A novel drug may help increase the effectiveness of radiation therapy for the most deadly form of brain cancer, report scientists at Virginia Commonwealth University Massey Cancer Center. In mouse models of human glioblastoma multiforme (GBM), the new drug helped significantly extend survival when used in combination with radiation therapy.
SironRX Therapeutics Inc., a privately-held, clinical-stage biotechnology company developing novel regenerative therapies to prevent scarring and promote dermal wound repair, is pleased to report that it has completed enrollment of patients in Cohort 1 of its placebo-controlled, randomized, dose escalation double-blind clinical study evaluating the safety and efficacy of JVS-100 to reduce scar formation and improve wound healing in patients receiving surgical sternotomy incisions.
While adverse reactions from smallpox vaccinations given to military personnel in the wake of renewed threats of bioterrorism remain minimal, the rate of cardiac complications has been higher than expected, according to a clinical review presented at an American Medical Society media briefing on cardiology today.
› Verified 5 days ago
| Dialysis patients with Hemoglobin data | 25 |
| Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 12 |
News Archive
EraGen Biosciences Inc., Madison, Wis., was congratulated today by SeqWright, Inc., Houston, on EraGen's successful FDA 510(k) market clearance of its MultiCode-RTx HSV 1 & 2 Kit. This new kit is the first FDA-cleared PCR-based qualitative in vitro diagnostic test for the detection and typing of HSV-1 and HSV-2 from vaginal lesion swab specimens in symptomatic female patients.
A novel drug may help increase the effectiveness of radiation therapy for the most deadly form of brain cancer, report scientists at Virginia Commonwealth University Massey Cancer Center. In mouse models of human glioblastoma multiforme (GBM), the new drug helped significantly extend survival when used in combination with radiation therapy.
SironRX Therapeutics Inc., a privately-held, clinical-stage biotechnology company developing novel regenerative therapies to prevent scarring and promote dermal wound repair, is pleased to report that it has completed enrollment of patients in Cohort 1 of its placebo-controlled, randomized, dose escalation double-blind clinical study evaluating the safety and efficacy of JVS-100 to reduce scar formation and improve wound healing in patients receiving surgical sternotomy incisions.
While adverse reactions from smallpox vaccinations given to military personnel in the wake of renewed threats of bioterrorism remain minimal, the rate of cardiac complications has been higher than expected, according to a clinical review presented at an American Medical Society media briefing on cardiology today.
› Verified 5 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 86 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 654 |
| Percentage of adult patients getting regular hemodialysis at the center | 96 |
| Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
EraGen Biosciences Inc., Madison, Wis., was congratulated today by SeqWright, Inc., Houston, on EraGen's successful FDA 510(k) market clearance of its MultiCode-RTx HSV 1 & 2 Kit. This new kit is the first FDA-cleared PCR-based qualitative in vitro diagnostic test for the detection and typing of HSV-1 and HSV-2 from vaginal lesion swab specimens in symptomatic female patients.
A novel drug may help increase the effectiveness of radiation therapy for the most deadly form of brain cancer, report scientists at Virginia Commonwealth University Massey Cancer Center. In mouse models of human glioblastoma multiforme (GBM), the new drug helped significantly extend survival when used in combination with radiation therapy.
SironRX Therapeutics Inc., a privately-held, clinical-stage biotechnology company developing novel regenerative therapies to prevent scarring and promote dermal wound repair, is pleased to report that it has completed enrollment of patients in Cohort 1 of its placebo-controlled, randomized, dose escalation double-blind clinical study evaluating the safety and efficacy of JVS-100 to reduce scar formation and improve wound healing in patients receiving surgical sternotomy incisions.
While adverse reactions from smallpox vaccinations given to military personnel in the wake of renewed threats of bioterrorism remain minimal, the rate of cardiac complications has been higher than expected, according to a clinical review presented at an American Medical Society media briefing on cardiology today.
› Verified 5 days ago
| Adult patients getting regular peritoneal dialysis at the center | 28 |
| Adult patient months included in Kt/V greater than or equal to 1.7 | 203 |
| Percentage of adult patients getting regular peritoneal dialysis at the center | 60 |
| Percentage of pediatric patients getting regular peritoneal dialysis at the center |
News Archive
EraGen Biosciences Inc., Madison, Wis., was congratulated today by SeqWright, Inc., Houston, on EraGen's successful FDA 510(k) market clearance of its MultiCode-RTx HSV 1 & 2 Kit. This new kit is the first FDA-cleared PCR-based qualitative in vitro diagnostic test for the detection and typing of HSV-1 and HSV-2 from vaginal lesion swab specimens in symptomatic female patients.
A novel drug may help increase the effectiveness of radiation therapy for the most deadly form of brain cancer, report scientists at Virginia Commonwealth University Massey Cancer Center. In mouse models of human glioblastoma multiforme (GBM), the new drug helped significantly extend survival when used in combination with radiation therapy.
SironRX Therapeutics Inc., a privately-held, clinical-stage biotechnology company developing novel regenerative therapies to prevent scarring and promote dermal wound repair, is pleased to report that it has completed enrollment of patients in Cohort 1 of its placebo-controlled, randomized, dose escalation double-blind clinical study evaluating the safety and efficacy of JVS-100 to reduce scar formation and improve wound healing in patients receiving surgical sternotomy incisions.
While adverse reactions from smallpox vaccinations given to military personnel in the wake of renewed threats of bioterrorism remain minimal, the rate of cardiac complications has been higher than expected, according to a clinical review presented at an American Medical Society media briefing on cardiology today.
› Verified 5 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at Us Renal Care Cheektowaga Dialysis with elevated calcium levels.
| Patients with hypercalcemia | 117 |
| Hypercalcemia patient months | 931 |
| Hypercalcemia patients with serumcalcium greater than 10.2 mg | 2 |
| Patients with Serumphosphor | 131 |
| Patients with Serumphosphor less than 3.5 mg/dL | 12 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 30 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 33 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 19 |
| Patients with Serumphosphor greater than 7 mg/dL | 6 |
News Archive
EraGen Biosciences Inc., Madison, Wis., was congratulated today by SeqWright, Inc., Houston, on EraGen's successful FDA 510(k) market clearance of its MultiCode-RTx HSV 1 & 2 Kit. This new kit is the first FDA-cleared PCR-based qualitative in vitro diagnostic test for the detection and typing of HSV-1 and HSV-2 from vaginal lesion swab specimens in symptomatic female patients.
A novel drug may help increase the effectiveness of radiation therapy for the most deadly form of brain cancer, report scientists at Virginia Commonwealth University Massey Cancer Center. In mouse models of human glioblastoma multiforme (GBM), the new drug helped significantly extend survival when used in combination with radiation therapy.
SironRX Therapeutics Inc., a privately-held, clinical-stage biotechnology company developing novel regenerative therapies to prevent scarring and promote dermal wound repair, is pleased to report that it has completed enrollment of patients in Cohort 1 of its placebo-controlled, randomized, dose escalation double-blind clinical study evaluating the safety and efficacy of JVS-100 to reduce scar formation and improve wound healing in patients receiving surgical sternotomy incisions.
While adverse reactions from smallpox vaccinations given to military personnel in the wake of renewed threats of bioterrorism remain minimal, the rate of cardiac complications has been higher than expected, according to a clinical review presented at an American Medical Society media briefing on cardiology today.
› Verified 5 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 50 |
| Patient months included in arterial venous fistula and catheter summaries | 346 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 64 |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 18 |
News Archive
EraGen Biosciences Inc., Madison, Wis., was congratulated today by SeqWright, Inc., Houston, on EraGen's successful FDA 510(k) market clearance of its MultiCode-RTx HSV 1 & 2 Kit. This new kit is the first FDA-cleared PCR-based qualitative in vitro diagnostic test for the detection and typing of HSV-1 and HSV-2 from vaginal lesion swab specimens in symptomatic female patients.
A novel drug may help increase the effectiveness of radiation therapy for the most deadly form of brain cancer, report scientists at Virginia Commonwealth University Massey Cancer Center. In mouse models of human glioblastoma multiforme (GBM), the new drug helped significantly extend survival when used in combination with radiation therapy.
SironRX Therapeutics Inc., a privately-held, clinical-stage biotechnology company developing novel regenerative therapies to prevent scarring and promote dermal wound repair, is pleased to report that it has completed enrollment of patients in Cohort 1 of its placebo-controlled, randomized, dose escalation double-blind clinical study evaluating the safety and efficacy of JVS-100 to reduce scar formation and improve wound healing in patients receiving surgical sternotomy incisions.
While adverse reactions from smallpox vaccinations given to military personnel in the wake of renewed threats of bioterrorism remain minimal, the rate of cardiac complications has been higher than expected, according to a clinical review presented at an American Medical Society media briefing on cardiology today.
› Verified 5 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | 92 |
| Hospitalization Rate in facility | 281.1 (Worse than Expected) |
| Hospitalization Rate: Upper Confidence Limit | 431.9 |
| Hospitalization Rate: Lower Confidence Limit | 187.3 |
News Archive
EraGen Biosciences Inc., Madison, Wis., was congratulated today by SeqWright, Inc., Houston, on EraGen's successful FDA 510(k) market clearance of its MultiCode-RTx HSV 1 & 2 Kit. This new kit is the first FDA-cleared PCR-based qualitative in vitro diagnostic test for the detection and typing of HSV-1 and HSV-2 from vaginal lesion swab specimens in symptomatic female patients.
A novel drug may help increase the effectiveness of radiation therapy for the most deadly form of brain cancer, report scientists at Virginia Commonwealth University Massey Cancer Center. In mouse models of human glioblastoma multiforme (GBM), the new drug helped significantly extend survival when used in combination with radiation therapy.
SironRX Therapeutics Inc., a privately-held, clinical-stage biotechnology company developing novel regenerative therapies to prevent scarring and promote dermal wound repair, is pleased to report that it has completed enrollment of patients in Cohort 1 of its placebo-controlled, randomized, dose escalation double-blind clinical study evaluating the safety and efficacy of JVS-100 to reduce scar formation and improve wound healing in patients receiving surgical sternotomy incisions.
While adverse reactions from smallpox vaccinations given to military personnel in the wake of renewed threats of bioterrorism remain minimal, the rate of cardiac complications has been higher than expected, according to a clinical review presented at an American Medical Society media briefing on cardiology today.
› Verified 5 days ago
The rate of readmission show you whether patients who were being treated regularly at Us Renal Care Cheektowaga Dialysis were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
| Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
| Readmission Rate in facility | 32 (As Expected) |
| Readmission Rate: Upper Confidence Limit | 44.8 |
| Readmission Rate: Lower Confidence Limit | 21.1 |
News Archive
EraGen Biosciences Inc., Madison, Wis., was congratulated today by SeqWright, Inc., Houston, on EraGen's successful FDA 510(k) market clearance of its MultiCode-RTx HSV 1 & 2 Kit. This new kit is the first FDA-cleared PCR-based qualitative in vitro diagnostic test for the detection and typing of HSV-1 and HSV-2 from vaginal lesion swab specimens in symptomatic female patients.
A novel drug may help increase the effectiveness of radiation therapy for the most deadly form of brain cancer, report scientists at Virginia Commonwealth University Massey Cancer Center. In mouse models of human glioblastoma multiforme (GBM), the new drug helped significantly extend survival when used in combination with radiation therapy.
SironRX Therapeutics Inc., a privately-held, clinical-stage biotechnology company developing novel regenerative therapies to prevent scarring and promote dermal wound repair, is pleased to report that it has completed enrollment of patients in Cohort 1 of its placebo-controlled, randomized, dose escalation double-blind clinical study evaluating the safety and efficacy of JVS-100 to reduce scar formation and improve wound healing in patients receiving surgical sternotomy incisions.
While adverse reactions from smallpox vaccinations given to military personnel in the wake of renewed threats of bioterrorism remain minimal, the rate of cardiac complications has been higher than expected, according to a clinical review presented at an American Medical Society media briefing on cardiology today.
› Verified 5 days ago
Hemodialysis treatment requires direct access to the bloodstream, which can be an opportunity for germs to enter the body and cause infection. This information shows how often patients at Us Renal Care Cheektowaga Dialysis get infections in their blood each year compared to the number of infections expected for the center based on the national average.
| Standard Infection Summary Ratio(SIR) Year | January, 2016 - December, 2016 |
| Infection Rate in facility | .16 (Better than Expected) |
| SIR: Upper Confidence Limit | .79 |
| SIR: Lower Confidence Limit | .01 |
News Archive
EraGen Biosciences Inc., Madison, Wis., was congratulated today by SeqWright, Inc., Houston, on EraGen's successful FDA 510(k) market clearance of its MultiCode-RTx HSV 1 & 2 Kit. This new kit is the first FDA-cleared PCR-based qualitative in vitro diagnostic test for the detection and typing of HSV-1 and HSV-2 from vaginal lesion swab specimens in symptomatic female patients.
A novel drug may help increase the effectiveness of radiation therapy for the most deadly form of brain cancer, report scientists at Virginia Commonwealth University Massey Cancer Center. In mouse models of human glioblastoma multiforme (GBM), the new drug helped significantly extend survival when used in combination with radiation therapy.
SironRX Therapeutics Inc., a privately-held, clinical-stage biotechnology company developing novel regenerative therapies to prevent scarring and promote dermal wound repair, is pleased to report that it has completed enrollment of patients in Cohort 1 of its placebo-controlled, randomized, dose escalation double-blind clinical study evaluating the safety and efficacy of JVS-100 to reduce scar formation and improve wound healing in patients receiving surgical sternotomy incisions.
While adverse reactions from smallpox vaccinations given to military personnel in the wake of renewed threats of bioterrorism remain minimal, the rate of cardiac complications has been higher than expected, according to a clinical review presented at an American Medical Society media briefing on cardiology today.
› Verified 5 days ago
Patients with anemia require blood transfusions if their anemia is not managed well by their dialysis center. This information shows whether Us Renal Care Cheektowaga Dialysis's rate of transfusions is better than expected, as expected, or worse than expected, compared to other centers that treat similar patients.
| Standard Transfusion Summary Ratio (STrR) Year | January, 2016 - December, 2016 |
| Patients in facility's Transfusion Summary | 83 |
| Transfusion Rate in facility | 70.1 (Worse than Expected) |
| Transfusion Rate: Upper Confidence Limit | 135.1 |
| Transfusion Rate: Lower Confidence Limit | 39.4 |
News Archive
EraGen Biosciences Inc., Madison, Wis., was congratulated today by SeqWright, Inc., Houston, on EraGen's successful FDA 510(k) market clearance of its MultiCode-RTx HSV 1 & 2 Kit. This new kit is the first FDA-cleared PCR-based qualitative in vitro diagnostic test for the detection and typing of HSV-1 and HSV-2 from vaginal lesion swab specimens in symptomatic female patients.
A novel drug may help increase the effectiveness of radiation therapy for the most deadly form of brain cancer, report scientists at Virginia Commonwealth University Massey Cancer Center. In mouse models of human glioblastoma multiforme (GBM), the new drug helped significantly extend survival when used in combination with radiation therapy.
SironRX Therapeutics Inc., a privately-held, clinical-stage biotechnology company developing novel regenerative therapies to prevent scarring and promote dermal wound repair, is pleased to report that it has completed enrollment of patients in Cohort 1 of its placebo-controlled, randomized, dose escalation double-blind clinical study evaluating the safety and efficacy of JVS-100 to reduce scar formation and improve wound healing in patients receiving surgical sternotomy incisions.
While adverse reactions from smallpox vaccinations given to military personnel in the wake of renewed threats of bioterrorism remain minimal, the rate of cardiac complications has been higher than expected, according to a clinical review presented at an American Medical Society media briefing on cardiology today.
› Verified 5 days ago
The rate of mortality show you whether patients who were being treated regularly at Us Renal Care Cheektowaga Dialysis lived longer than expected (better than expected), don’t live as long as expected (worse than expected), or lived as long as expected (as expected), compared to similar patients treated at other facilities.
| Standard Survival Summary Ratio(SIR) Year | January, 2013 - December, 2016 |
| Patients in facility's Survival Summary | 450 |
| Mortality Rate in facility | 20.9 (As Expected) |
| Mortality Rate: Upper Confidence Limit | 26.4 |
| Mortality Rate: Lower Confidence Limit | 16.3 |
News Archive
EraGen Biosciences Inc., Madison, Wis., was congratulated today by SeqWright, Inc., Houston, on EraGen's successful FDA 510(k) market clearance of its MultiCode-RTx HSV 1 & 2 Kit. This new kit is the first FDA-cleared PCR-based qualitative in vitro diagnostic test for the detection and typing of HSV-1 and HSV-2 from vaginal lesion swab specimens in symptomatic female patients.
A novel drug may help increase the effectiveness of radiation therapy for the most deadly form of brain cancer, report scientists at Virginia Commonwealth University Massey Cancer Center. In mouse models of human glioblastoma multiforme (GBM), the new drug helped significantly extend survival when used in combination with radiation therapy.
SironRX Therapeutics Inc., a privately-held, clinical-stage biotechnology company developing novel regenerative therapies to prevent scarring and promote dermal wound repair, is pleased to report that it has completed enrollment of patients in Cohort 1 of its placebo-controlled, randomized, dose escalation double-blind clinical study evaluating the safety and efficacy of JVS-100 to reduce scar formation and improve wound healing in patients receiving surgical sternotomy incisions.
While adverse reactions from smallpox vaccinations given to military personnel in the wake of renewed threats of bioterrorism remain minimal, the rate of cardiac complications has been higher than expected, according to a clinical review presented at an American Medical Society media briefing on cardiology today.
› Verified 5 days ago
Us Renal Care Cheektowaga Dialysis Location: 2875 Union Road, Suite 13 C/d, Cheektowaga, New York, 14227 Phone: (716) 684-0276 |
News Archive
EraGen Biosciences Inc., Madison, Wis., was congratulated today by SeqWright, Inc., Houston, on EraGen's successful FDA 510(k) market clearance of its MultiCode-RTx HSV 1 & 2 Kit. This new kit is the first FDA-cleared PCR-based qualitative in vitro diagnostic test for the detection and typing of HSV-1 and HSV-2 from vaginal lesion swab specimens in symptomatic female patients.
A novel drug may help increase the effectiveness of radiation therapy for the most deadly form of brain cancer, report scientists at Virginia Commonwealth University Massey Cancer Center. In mouse models of human glioblastoma multiforme (GBM), the new drug helped significantly extend survival when used in combination with radiation therapy.
SironRX Therapeutics Inc., a privately-held, clinical-stage biotechnology company developing novel regenerative therapies to prevent scarring and promote dermal wound repair, is pleased to report that it has completed enrollment of patients in Cohort 1 of its placebo-controlled, randomized, dose escalation double-blind clinical study evaluating the safety and efficacy of JVS-100 to reduce scar formation and improve wound healing in patients receiving surgical sternotomy incisions.
While adverse reactions from smallpox vaccinations given to military personnel in the wake of renewed threats of bioterrorism remain minimal, the rate of cardiac complications has been higher than expected, according to a clinical review presented at an American Medical Society media briefing on cardiology today.
› Verified 5 days ago